24 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
will, in the future, be successful in fully or even adequately hedging our currency risk.
Table of Contents
Risks Related to the Development of Our … the debt host agreement in accordance with ASC 815, Derivatives and Hedging. Accordingly, we recognized a derivative liability at fair value
424B7
OBSVF
ObsEva SA
3 Mar 22
Prospectus with selling stockholder info
4:43pm
, the selling shareholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the common shares … in the course of hedging in positions they assume. The selling shareholders may also sell common shares short and deliver common shares covered
F-3
OBSVF
ObsEva SA
17 Feb 22
Shelf registration (foreign)
4:14pm
. In connection with sales of the common shares or otherwise, the selling shareholders may enter into hedging transactions with broker-dealers, which … may in turn engage in short sales of the common shares in the course of hedging in positions they assume. The selling shareholders may also sell common
6-K
EX-99.3
OBSVF
ObsEva SA
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
and acknowledges that (y) one or more Purchasers may sell Conversion Shares or Warrant Shares or engage in hedging activities at various times during … the period that the Securities are outstanding and (z) such sales or hedging activities (if any) may negatively affect the Company’s stock price
424B7
761a3rvdv5y
23 Nov 21
Prospectus with selling stockholder info
4:06pm
F-3
j5a3muz7
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K/A
EX-99.2
zultu
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.5
yxi0six8f
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.2
e0742rzjf783p
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.5
ycrb19knz
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
424B5
qnb cqv45i5r
5 Mar 21
Prospectus supplement for primary offering
7:55am
424B5
v6cd4houkgsg7wlc
8 Sep 20
Prospectus supplement for primary offering
7:31am
424B5
3c23wowi d3xg
7 Aug 19
Prospectus supplement for primary offering
8:18am
6-K
EX-99.1
wdeo3hcucu
7 Aug 19
Current report (foreign)
7:21am
424B5
7rxxy4c
20 Jun 18
Prospectus supplement for primary offering
5:32pm
424B5
ljbk9j
18 Jun 18
Prospectus supplement for primary offering
9:15pm